- 英文名称1,3,5-Trimethyl-4-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-yl)-1H-Pyrazole
- 中文名称1,3,5-三甲基-4-(4,4,5,5-四甲基-1,3,2-二氧硼烷-2-基)-1H-吡唑
- IUPAC名称1,3,5-trimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
- 其它别名1,3,5-三甲基-4-(4,4,5,5-四甲基-1,3,2-二氧硼戊环-2-基)吡唑; 2-(1,3,5-Trimethyl-4-Pyrazolyl)-4,4,5,5-Tetramethyl-1,3,2-Dioxaborolane
- CAS编号844891-04-9
- MFCD编号:MFCD06659062
- EINECS号:677-047-4
- 分子式:C12H21BN2O2
- 分子量:236.12
- 产品CID: 1833610
- 产品分类有机原料→分子砌块→芳杂环类化合物→吡唑类化合物
相似化合物
847818-62-6 1073354-70-7 1036991-40-8欧盟法规
C&L通报上下游产品
CAS号857530-80-4 3,5-二甲基吡唑-4-硼酸频哪醇酯 | CAS号74-88-4 碘甲烷 | CAS号61676-62-8 2-异丙氧基-4,4,5,5-... | CAS号76-09-5 频哪醇 | CAS号847818-62-6 (1,3,5-三甲基-1H-吡... | CAS号3398-16-1 3,5-二甲基-4-溴吡唑 | CAS号15801-69-1 4-溴-1,3,5-三甲基吡唑合成工艺路线路线简述
- 合成目标产物 1,3,5-Trimethyl-4-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-yl)-1H-Pyrazole 主要起始原料 2-Isopropoxy-4,4,5,5-Tetramethyl-1,3,2-Dioxaborolane
- 76-09-5 + 847818-62-6 = 844891-04-9
反应条件:1.1 Solvents: Tetrahydrofuran; 2 H,Rt
标题:Synthesis Of Pinacol Esters Of 1-Alkyl-1H-Pyrazol-5-Yl- And 1-Alkyl-1H-Pyrazol-4-Ylboronic Acids
作者:Ivachtchenko,Alexandre V.; Et Al
参考文献:Journal Of Heterocyclic Chemistry 日期:2004 卷标:41(6) 页码:931-939]
15801-69-1 = 844891-04-9
反应条件:1.1 Reagents: Butyllithium Solvents: Tetrahydrofuran,Hexane; -90 °C; < -80 °C; 1 H,-90 °C1.2 Reagents: Trimethyl Borate; 0.5 H,-70 °C; -70 °C -> -15 °C1.3 Reagents: Ammonium Chloride Solvents: Water; Neutralized,-15 °C; -15 °C -> Rt; 1 H,Rt2.1 Solvents: Tetrahydrofuran; 2 H,Rt
标题:Synthesis Of Pinacol Esters Of 1-Alkyl-1H-Pyrazol-5-Yl- And 1-Alkyl-1H-Pyrazol-4-Ylboronic Acids
作者:Ivachtchenko,Alexandre V.; Et Al
参考文献:Journal Of Heterocyclic Chemistry 日期:2004 卷标:41(6) 页码:931-939]
3398-16-1 = 844891-04-9
反应条件:1.1 Reagents: Potassium Hydroxide Solvents: Ethanol; 1.5 H,Reflux2.1 Reagents: Butyllithium Solvents: Tetrahydrofuran,Hexane; -90 °C; < -80 °C; 1 H,-90 °C2.2 Reagents: Trimethyl Borate; 0.5 H,-70 °C; -70 °C -> -15 °C2.3 Reagents: Ammonium Chloride Solvents: Water; Neutralized,-15 °C; -15 °C -> Rt; 1 H,Rt3.1 Solvents: Tetrahydrofuran; 2 H,Rt
标题:Synthesis Of Pinacol Esters Of 1-Alkyl-1H-Pyrazol-5-Yl- And 1-Alkyl-1H-Pyrazol-4-Ylboronic Acids
作者:Ivachtchenko,Alexandre V.; Et Al
参考文献:Journal Of Heterocyclic Chemistry 日期:2004 卷标:41(6) 页码:931-939]
15801-69-1 + 185990-03-8 = 844891-04-9 + 387353-95-9
反应条件:1.1 Reagents: Potassium Methoxide Solvents: Methyl Ether; 10 Min,30 °C1.2 30 °C; 1 H,30 °C
标题:Boryl Substitution Of Functionalized Aryl-,Heteroaryl- And Alkenyl Halides With Silylborane And An Alkoxy Base: Expanded Scope And Mechanistic Studies
作者:Yamamoto,Eiji; Et Al
参考文献:Chemical Science 日期:2015 卷标:6(5) 页码:2943-2951
3,5-二甲基-4-溴吡唑置于氢氧化钾,正丁基锂,4 A Molecular Sieve体系中,用 四氢呋喃,乙醇,正己烷 作为反应溶剂,化学反应 6.0H,反应生成 1,3,5-三甲基-1H-吡唑-4-硼酸频哪醇酯
参考文献:1-烷基-1 H-吡唑-5-基和1烷基-1 H-吡唑-4-基硼酸频哪醇酯的合成
标题:1-烷基-1 H-吡唑-5-基和1烷基-1 H-吡唑-4-基硼酸频哪醇酯的合成
摘要:从1 H-吡唑开始,合成并表征了多种1-烷基-1 H-吡唑-4-基和1-烷基-1 H-吡唑-5-基硼酸及其频哪醇酯.所述方法中的关键步骤是吡唑环的区域选择性锂化.合成的松果酸酯在长期保存下是稳定的,可以用作有机合成中的方便试剂.
DOI:10.1002/jhet.5570410612
海关参考信息
- 2905122000-异丙醇
2905143000-叔丁醇
2905310000-1,2-乙二醇
2905320000-1,2-丙二醇 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
专利信息
专利号:US-9839642-B2
优先权日:2014-05-09
标 题:Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors
发明人:TANG HAIFENG; YANG SHU-WEI; MANDAL MIHIR; SU JING; LI GUOQING; PAN WEIDONG; TANG HAIQUN; DEJESUS REYNALDA; PAN JIANPING; HAGMANN WILLIAM; DING FA-XIANG; XIAO LI; PASTERNAK ALEXANDER; HUANG YUHUA; DONG SHUZHI; YANG DEXI
权利人:MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula I that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.
专利号:WO-2010065383-A1
优先权日:2008-11-25
标 题 :Calcilytic compounds
发明人:CASILLAS LINDA N; CHARNLEY ADAM KENNETH; HARRIS PHILIP ANTHONY; JEONG JAE U; MARQUIS ROBERT W; RAMANJULU JOSHI M; TROUT ROBERT
权利人:GLAXOSMITHKLINE LLC; CASILLAS LINDA N; CHARNLEY ADAM KENNETH; HARRIS PHILIP ANTHONY; JEONG JAE U; MARQUIS ROBERT W; RAMANJULU JOSHI M; TROUT ROBERT
摘要:Novel calcilytic compounds, pharmaceutical compositions, methods of synthesis and methods of using them are provided.